These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
Nevada
|
87-0479286
|
|
|
(State of jurisdiction of Incorporation)
|
(I.R.S. Employer Identification No.)
|
|
|
31 N. Suffolk Lane, Lake Forest, Illinois
|
60045
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
o
|
Accelerated filer
o
|
|
Non-accelerated filer
o
|
Smaller reporting company
x
|
|
(Do not check if a smaller reporting company)
|
|
|
|
Closing Bid Prices(1)
|
||||||||
|
High
|
Low
|
|||||||
|
Year Ended December 31, 2010
|
||||||||
|
4th Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
3rd Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
2nd Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
1st Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
Year Ended December 31, 2009
|
||||||||
|
4th Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
3rd Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
2nd Quarter
|
$ | 0.10 | $ | 0.10 | ||||
|
1st Quarter
|
$ | 0.10 | $ | 0.10 | ||||
| Page | |
|
Report of Independent Registered Public Accounting Firm
|
F-1
|
|
Balance Sheets, December 31, 2010, September 30, 2010 and 2009
|
F-2
|
|
Statements of Operations for the three months ended December 31, 2010 and 2009 (2009 unaudited),
for the years ended September 30, 2010 and 2009 and for the Period from May 27, 2004
Date of Inception of the Development Stage) through December 31, 2010
|
F-3
|
|
Statements of Stockholders’ Deficit for the Period from May 27, 2004 (Date of Inception of
the Development Stage) through September 30, 2007, for the Years Ended September 30, 2008,
2009 and 2010, and for the Three Months Ended December 31, 2010
|
F-4
|
|
Statements of Cash Flows for the three months ended December 31, 2010 and 2009 (2009 unaudited),
for the years ended September 30, 2010 and 2009 and for the Period from May 27, 2004
(Date of Inception of the Development Stage) through December 31, 2010
|
F-5
|
|
Notes to Financial Statements
|
F-6
|
|
To the Board of Directors and the Shareholders
|
|
Acquired Sales Corporation
|
|
ACQUIRED SALES CORP.
|
||||||||||||
|
(a development stage enterprise)
|
||||||||||||
|
Balance Sheets
|
||||||||||||
|
December 31,
|
September 30,
|
|||||||||||
|
2010
|
2010
|
2009
|
||||||||||
|
ASSETS
|
||||||||||||
|
Current Assets:
|
||||||||||||
|
Cash
|
$ | 5,148 | $ | - | $ | 12 | ||||||
|
Prepaid expense
|
- | - | 25 | |||||||||
|
TOTAL ASSETS
|
$ | 5,148 | $ | - | $ | 37 | ||||||
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||||||
|
Current Liabilities:
|
||||||||||||
|
Deficit in bank
|
$ | - | $ | 46 | $ | - | ||||||
|
Accounts payable
|
17,055 | 14,389 | 2,371 | |||||||||
|
Notes payable - related parties
|
44,000 | 24,000 | 10,000 | |||||||||
|
Note interest payable - related party
|
- | - | 82 | |||||||||
|
Total Current Liabilities
|
61,055 | 38,435 | 12,453 | |||||||||
|
Stockholders' Deficit:
|
||||||||||||
|
Preferred stock, $0.001 par value, 10,000,000 shares
|
||||||||||||
|
authorized, no shares issued and outstanding
|
- | - | - | |||||||||
|
Common stock, $0.001 par value, 50,000,000 shares
|
||||||||||||
|
authorized, 5,832,482 shares issued and outstanding
|
5,833 | 5,833 | 5,833 | |||||||||
|
Additional paid-in capital
|
454,754 | 145,967 | 145,967 | |||||||||
|
Deficit accumulated prior to the development stage
|
(69,151 | ) | (69,151 | ) | (69,151 | ) | ||||||
|
Deficit accumulated during the development stage
|
(447,343 | ) | (121,084 | ) | (95,065 | ) | ||||||
|
Total Stockholders' Deficit
|
(55,907 | ) | (38,435 | ) | (12,416 | ) | ||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
|
$ | 5,148 | $ | - | $ | 37 | ||||||
|
See accompanying notes to the financial statements.
|
||||||||||||
|
ACQUIRED SALES CORP.
|
||||||||||||||||||||
|
(a development stage enterprise)
|
||||||||||||||||||||
|
Statements of Operations
|
||||||||||||||||||||
|
For the period
|
||||||||||||||||||||
|
May 27, 2004
|
||||||||||||||||||||
|
(Date of Inception
|
||||||||||||||||||||
|
For the Three Months Ended
|
For the Years Ended
|
of the Development
|
||||||||||||||||||
|
December 31,
|
September 30,
|
Stage) through
|
||||||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
December 31, 2010
|
||||||||||||||||
|
(Unaudited)
|
||||||||||||||||||||
|
Expenses:
|
||||||||||||||||||||
|
General and administrative
|
$ | (325,210 | ) | $ | (5,099 | ) | $ | (23,946 | ) | $ | (11,669 | ) | $ | (497,767 | ) | |||||
|
Waiver of tax liability penalty
|
- | - | - | - | 60,364 | |||||||||||||||
|
Interest
|
(1,049 | ) | (407 | ) | (2,073 | ) | (667 | ) | (9,940 | ) | ||||||||||
|
Net Loss
|
$ | (326,259 | ) | $ | (5,506 | ) | $ | (26,019 | ) | $ | (12,336 | ) | $ | (447,343 | ) | |||||
|
Basic and diluted loss per share
|
$ | (0.06 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | ||||||||
|
Basic and diluted weighted average
|
||||||||||||||||||||
|
common shares outstanding
|
5,832,482 | 5,832,482 | 5,832,482 | 5,832,482 | ||||||||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||||||||||
|
ACQUIRED SALES CORP.
|
||||||||||||||||||||||||
|
(a development stage enterprise)
|
||||||||||||||||||||||||
|
Statements of Stockholders' Deficit
|
||||||||||||||||||||||||
|
for the Period from May 27, 2004 (Date of Inception of the Development Stage) through September 30, 2007,
|
||||||||||||||||||||||||
|
for the Years Ended September 30, 2008, 2009 and 2010 and for the Three Months Ended December 31, 2010
|
||||||||||||||||||||||||
|
Deficit
|
Deficit
|
|||||||||||||||||||||||
|
Accumulated
|
Accumulated
|
Total
|
||||||||||||||||||||||
|
Additional
|
Prior to the
|
During the
|
Stockholders'
|
|||||||||||||||||||||
|
Common Stock
|
Paid-in
|
Development
|
Development
|
Equity
|
||||||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Stage
|
Stage
|
(Deficit)
|
|||||||||||||||||||
|
Balance, May 27, 2004 (Date of
|
||||||||||||||||||||||||
|
Inception of the Development
|
||||||||||||||||||||||||
|
Stage)
|
684,990 | $ | 685 | $ | (685 | ) | $ | (69,151 | ) | $ | - | $ | (69,151 | ) | ||||||||||
|
Common stock issued for cash,
|
||||||||||||||||||||||||
|
May 2004, $0.001 per share
|
4,000,000 | 4,000 | 36,000 | - | - | 40,000 | ||||||||||||||||||
|
Common stock redeemed for
|
||||||||||||||||||||||||
|
cash, May 2004, $0.001
|
||||||||||||||||||||||||
|
per share
|
(19,005 | ) | (19 | ) | (171 | ) | - | - | (190 | ) | ||||||||||||||
|
Capital contributed by officer,
|
||||||||||||||||||||||||
|
September 30, 2004
|
- | - | 20 | - | - | 20 | ||||||||||||||||||
|
Conversion of note payable to
|
||||||||||||||||||||||||
|
related party into common stock
|
||||||||||||||||||||||||
|
July 2007, $0.086 per share
|
1,166,497 | 1,167 | 98,833 | - | - | 100,000 | ||||||||||||||||||
|
Issuance of 175,000 warrants
|
||||||||||||||||||||||||
|
for services, August 2007,
|
||||||||||||||||||||||||
|
$0.068 per warrant
|
- | - | 11,970 | - | - | 11,970 | ||||||||||||||||||
|
Net loss through September 30, 2007
|
- | - | - | - | (48,023 | ) | (48,023 | ) | ||||||||||||||||
|
Balance, September 30, 2007
|
5,832,482 | 5,833 | 145,967 | (69,151 | ) | (48,023 | ) | 34,626 | ||||||||||||||||
|
Net loss
|
- | - | - | - | (34,706 | ) | (34,706 | ) | ||||||||||||||||
|
Balance, September 30, 2008
|
5,832,482 | 5,833 | 145,967 | (69,151 | ) | (82,729 | ) | (80 | ) | |||||||||||||||
|
Net loss
|
- | - | - | - | (12,336 | ) | (12,336 | ) | ||||||||||||||||
|
Balance, September 30, 2009
|
5,832,482 | 5,833 | 145,967 | (69,151 | ) | (95,065 | ) | (12,416 | ) | |||||||||||||||
|
Net loss
|
- | - | - | - | (26,019 | ) | (26,019 | ) | ||||||||||||||||
|
Balance, September 30, 2010
|
5,832,482 | 5,833 | 145,967 | (69,151 | ) | (121,084 | ) | (38,435 | ) | |||||||||||||||
|
Stock Option Compensation
|
- | - | 308,787 | - | - | 308,787 | ||||||||||||||||||
|
Net loss
|
- | - | - | - | (326,259 | ) | (326,259 | ) | ||||||||||||||||
|
Balance, December 31, 2010
|
5,832,482 | 5,833 | 454,754 | (69,151 | ) | (447,343 | ) | (55,907 | ) | |||||||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||||||||||||||
|
ACQUIRED SALES CORP.
|
||||||||||||||||||||
|
(a development stage enterprise)
|
||||||||||||||||||||
|
Statements of Cash Flows
|
||||||||||||||||||||
|
For the period
|
||||||||||||||||||||
|
May 27, 2004
|
||||||||||||||||||||
|
(Date of Inception
|
||||||||||||||||||||
|
For the Three Months Ended
|
For the Years Ended
|
of the Development
|
||||||||||||||||||
|
December 31,
|
September 30,
|
Stage) through
|
||||||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
December 31, 2010
|
||||||||||||||||
|
(unaudited)
|
||||||||||||||||||||
|
Cash Flows from Operating Activities:
|
||||||||||||||||||||
|
Net loss
|
$ | (326,259 | ) | $ | (5,506 | ) | $ | (26,019 | ) | $ | (12,336 | ) | $ | (447,343 | ) | |||||
|
Adjustments to reconcile net loss to net cash
|
||||||||||||||||||||
|
used in operating activities:
|
||||||||||||||||||||
|
Expenses paid by capital contributed by officer
|
- | - | - | - | 20 | |||||||||||||||
|
Share-based compensation
|
308,787 | - | - | - | 308,787 | |||||||||||||||
|
Waiver of tax liability penalty
|
- | - | - | - | (60,364 | ) | ||||||||||||||
|
Issuance of warrants for services
|
- | - | - | - | 11,970 | |||||||||||||||
|
Changes in assets and liabilities:
|
||||||||||||||||||||
|
Prepaid expense
|
- | 6 | 25 | (25 | ) | - | ||||||||||||||
|
Accounts payable
|
2,666 | 1,893 | 12,018 | 1,621 | 17,055 | |||||||||||||||
|
Note interest payable - related party
|
- | (82 | ) | (82 | ) | 82 | - | |||||||||||||
|
Payroll tax penalties and accrued interest
|
- | - | - | - | (8,787 | ) | ||||||||||||||
|
Net Cash Used by Operating Activities
|
(14,806 | ) | (3,689 | ) | (14,058 | ) | (10,658 | ) | (178,662 | ) | ||||||||||
|
Cash Flows from Financing Activities:
|
||||||||||||||||||||
|
Deficit in bank
|
(46 | ) | - | 46 | - | - | ||||||||||||||
|
Proceeds from issuance of note payable to
|
||||||||||||||||||||
|
related parties
|
20,000 | 10,000 | 14,000 | 10,000 | 239,000 | |||||||||||||||
|
Payment of principal on note payable to
|
||||||||||||||||||||
|
related parties
|
- | - | - | - | (95,000 | ) | ||||||||||||||
|
Proceeds from issuance of common stock
|
- | - | - | - | 40,000 | |||||||||||||||
|
Redemption of common stock
|
- | - | - | - | (190 | ) | ||||||||||||||
|
Net Cash Provided by Financing Activities:
|
19,954 | 10,000 | 14,046 | 10,000 | 183,810 | |||||||||||||||
|
Net Increase (Decrease) in Cash
|
5,148 | 6,311 | (12 | ) | (658 | ) | 5,148 | |||||||||||||
|
Cash at beginning of period
|
- | 12 | 12 | 670 | - | |||||||||||||||
|
Cash at End of Period
|
$ | 5,148 | $ | 6,323 | $ | - | $ | 12 | $ | 5,148 | ||||||||||
|
Supplemental Cash Flow Information
|
||||||||||||||||||||
|
Cash paid for interest
|
$ | 1,049 | $ | 478 | $ | 2,155 | $ | 585 | ||||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||||||||||
|
Three Months Ended December 31, 2010
|
|||
|
Weighted-average volatility
|
77.88 | % | |
|
Expected dividends
|
0 | % | |
|
Expected term (years)
|
5.20 | ||
|
Risk-free interest rate
|
1.11 | % | |
|
Weighted-
|
|||||||||||||||
|
Weighted -
|
Average
|
||||||||||||||
|
Average
|
Remaining
|
Aggregate
|
|||||||||||||
|
Exercise
|
Contractual
|
Instrinsic
|
|||||||||||||
|
Options
|
Shares
|
Price
|
Term (Years)
|
Value
|
|||||||||||
|
Outstanding, October 1, 2010
|
- | $ | - | ||||||||||||
|
Granted during the three months ended December 31, 2010
|
12,600,000 | 0.10 | |||||||||||||
|
Outstanding, December 31, 2010
|
12,600,000 | $ | 0.10 | 5.2 | $ | - | |||||||||
|
Exercisable, December 31, 2010
|
- | $ | - | - | $ | - | |||||||||
|
December 31,
|
September 30,
|
|||||||||||
|
2010
|
2010
|
2009
|
||||||||||
|
Warrants outstanding
|
$ | - | $ | 4,465 | $ | 4,465 | ||||||
|
Stock option compensation
|
115,177 | - | - | |||||||||
|
Operating loss carryforwards
|
148,026 | 37,098 | 28,252 | |||||||||
|
Total deferred tax assets
|
263,203 | 41,563 | 32,717 | |||||||||
|
Less: Valuation allowance
|
(263,203 | ) | (41,563 | ) | (32,717 | ) | ||||||
|
Net Deferred Tax Asset
|
$ | - | $ | - | $ | - | ||||||
|
December 31,
|
September 30,
|
|||||||||||
|
2010
|
2010
|
2009
|
||||||||||
|
Federal income tax benefit
|
||||||||||||
|
at statutory rate of 34%
|
$ | (110,928 | ) | $ | (8,846 | ) | $ | (4,194 | ) | |||
|
Change in valuation allowance
|
110,928 | 8,846 | 4,194 | |||||||||
|
Provision for income taxes
|
$ | - | $ | - | $ | - | ||||||
|
Assets
|
||||
|
Cash and total current assets
|
$ | 105,148 | ||
|
Long-term 5% notes receivable from Cogility
|
820,000 | |||
|
Total Assets
|
$ | 925,148 | ||
|
Liabilities and Stockholders' Equity
|
||||
|
Accounts payable
|
$ | 17,055 | ||
|
Notes payable to related parties
|
44,000 | |||
|
Total current liabilities
|
61,055 | |||
|
Long-term liabilities
|
||||
|
3% Notes payable to related parties; $400,000 face amount;
|
||||
|
less $132,828 unamortized discount based on effective interest
|
||||
|
rate of 14.0%
|
267,172 | |||
|
3% Notes payable; $520,000 face amount; less $172,675
|
||||
|
unamortized discount based on effective interest rate of 11.9%
|
347,325 | |||
|
Total liabilities
|
675,552 | |||
|
Stockholders' equity
|
||||
|
Common stock
|
5,833 | |||
|
Additional paid-in capital
|
760,257 | |||
|
Deficit accumulated prior to the development stage
|
(69,151 | ) | ||
|
Deficit accumulated during the development stage
|
(447,343 | ) | ||
|
Total stockholders' equity
|
249,596 | |||
|
Total Liabilities and Stockholders' Equity
|
$ | 925,148 | ||
|
·
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and disposition of an issuer;
|
|
·
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management and directors of the issuer; and
|
|
·
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's assets that could have a material adverse effect on the financial statements.
|
|
·
|
There existed a lack of segregation of duties in regard to the Company’s financial reporting, procedures for depositing of funds, procedures for cash disbursements, procedures for checkbook entries, period close procedures, and procedures for financial statement preparation.
|
|
·
|
During November 2009, the Company increased its Board of Directors to seven members, and added as an additional independent member Mr. Vincent J. Mesolella. Mr. Mesolella is the Chairman of the Narragansett Bay Commission, Providence, Rhode Island. Mr. Mesolella is also the Chief Executive Officer of REI, Inc., a diversified real estate development company. Mr. Mesolella has previously served as the Chairman of the Audit Committee of the Board of Directors of a publicly traded company.
|
|
·
|
Beginning in March 2009, the Company had begun emailing or mailing to Mr. Mesolella a copy of each monthly statement from its bank summarizing all activity in the Company’s checking account, for review and questioning as appropriate. The purpose of Mr. Mesolella’s involvement is to provide monitoring, oversight and assistance to Mr. Jacobs, our principal financial and executive officer in the preparation and reporting of the Company’s financial statements.
|
|
Name
|
Age
|
Position
|
||
|
Gerard M. Jacobs
|
55
|
Chairman, chief executive officer, president, secretary, treasurer
|
||
|
Joshua A. Bloom, M.D.
|
54
|
Director
|
||
|
Roger S. Greene
|
55
|
Director
|
||
|
James S. Jacobs, MD
|
56
|
Director
|
||
|
Michael D. McCaffrey
|
64
|
Director
|
||
|
Richard E. Morrissy
|
56
|
Director
|
||
|
Vincent J. Mesolella
|
61
|
Director
|
||
|
Annual Compensation
|
Long-Term Compensation
|
|||||||||||||
|
Common
|
||||||||||||||
|
Shares
|
||||||||||||||
|
Underlying
|
All
|
|||||||||||||
|
Restricted
|
Options
|
Other
|
||||||||||||
|
Other Annual
|
Stock
|
Granted
|
Compensation
|
|||||||||||
|
Name and Position
|
Year
|
Salary
|
Bonus
|
Compensation
|
Awards
|
($)
|
||||||||
|
Gerard M. Jacobs
CEO.
(1)
|
2010
2009
|
$ -
$ -
|
-
|
-
|
-
|
$769,560
(2)
|
-
|
|||||||
|
(1)
|
Mr. Jacobs has been issued options to purchase 12,100,000 shares of our common stock at a purchase price of $0.10 per share. These options will vest upon closing of the Cogility acquisition and expire on November 4, 2020.
|
|
(2)
|
The weighted-average grant-date fair value of options granted during the three months ended December 31, 2010 was $0.0636 per share. The Company recognizes compensation expense for stock-based awards expected to vest on a straight-line basis over the requisite service period of the award based on their grant date fair value. The Company estimates the fair value of stock options using a Black-Scholes option pricing model which requires management to make estimates for certain assumptions regarding risk-free interest rate, expected life of options, expected volatility of stock and expected dividend yield of stock.
|
|
Name
|
Fees earned or paid in cash ($)
|
Stock awards ($)
|
Option awards
($)
(1)(2)
|
Non-equity incentive plan compensation ($)
|
Nonqualified deferred
compensation earnings
($)
|
All other compensation ($)
|
Total
($)
|
|
|
Gerard M. Jacobs(3)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
Joshua A. Bloom
|
-
|
-
|
$6,360
|
-
|
-
|
-
|
$6,360
|
|
|
Roger S. Greene
|
-
|
-
|
$6,360
|
-
|
-
|
-
|
$6,360
|
|
|
Michael McCaffrey
|
-
|
-
|
$6,360
|
-
|
-
|
-
|
$6,360
|
|
|
Vincent J. Mesolella
|
-
|
-
|
$6,360
|
-
|
-
|
-
|
$6,360
|
|
|
Richard E. Morrissy
|
-
|
-
|
$6,360
|
-
|
-
|
-
|
$6,360
|
|
|
(1)
|
These options entitle the holder to purchase shares of our common stock at a purchase price of $0.10 per share. These options will vest upon closing of the Cogility acquisition and expire on November 4,
2020.
|
|
(2)
|
The weighted-average grant-date fair value of options granted during the three months ended December 31, 2010 was $0.0636 per share. The Company recognizes compensation expense for stock-based awards expected to vest on a straight-line basis over the requisite service period of the award based on their grant date fair value. The Company estimates the fair value of stock options using a Black-Scholes option pricing model which requires management to make estimates for certain assumptions regarding risk-free interest rate, expected life of options, expected volatility of stock and expected dividend yield of stock.
|
|
(3)
|
Mr. Jacobs’ option compensation described in the preceding table is deemed to be executive compensation.
|
|
Outstanding Equity Awards At Fiscal Year End
(see description of columns (a) through (j) below)
Option Awards Stock Awards
|
|
(a) (b) (c) (d) (e) (f) (g) (h) (i) (j)
Gerard M. Jacobs, CEO 12,100,000 - - $0.10 11/4/20 12,100,000 $769,560
|
|
(a)
|
The name of the named executive officer (column (a));
|
|
(b)
|
|
(c)
|
|
(d)
|
|
(e)
|
|
(f)
|
|
(g)
|
|
(h)
|
|
(i)
|
|
(j)
|
|
Name and Address
|
Amount and Nature of Beneficial Ownership
|
Percent of Voting Securities
|
||
|
Leonard D. Hall (1)
|
600,000
|
10.3%
|
||
|
Gerard M. Jacobs (2)
|
19,666,497
|
337.2%
|
||
|
Joshua A. Bloom, M.D. (3)
|
100,000
|
1.7%
|
||
|
Roberti Jacobs Family Trust (4)
|
4,666,497
|
80.0%
|
||
|
Roger S. Greene (5)
|
350,000
|
6.0%
|
||
|
Michael D. McCaffrey (6)
|
100,000
|
1.7%
|
||
|
Richard E. Morrissy (7)
|
100,000
|
1.7%
|
||
|
Vincent J. Mesolella (8)
|
350,000
|
6.0%
|
||
|
Joseph S. Keller (9)
|
3,000,000
|
51.4%
|
||
|
John and Susan Heider (10)
|
1,500,000
|
25.7%
|
||
|
Total Officers and Directors as group (6 persons)
|
19,781,497 (11)
|
|||
|
(1)
|
The address for Mr. Hall is 1029 E. 380 North, American Fork, Utah 84003.
|
|
(2)
|
The address for Mr. Jacobs is 31 N. Suffolk Lane, Lake Forest, Illinois 60045. Mr. Jacobs, our chairman, chief executive officer, president, secretary, and treasurer has voting control over 19,666,497 shares, consisting of: (a) 1,166,497 Company shares owned by the Roberti Jacobs Family Trust, over which Mr. Jacobs has voting control via a 2007 shareholders agreement; (b) 2,900,000 Company shares owned by unrelated shareholders of the Company, over which Mr. Jacobs has voting control via a 2007 shareholders agreement; (c) 12,100,000 options at $0.10 per share, the vesting of which is contingent upon the closing of the merger with Cogility; and (d) 3,500,000 warrants at $0.10 per share, owned by the Roberti Jacobs Family Trust, over which Mr. Jacobs has voting control via a 2007 shareholders agreement.
|
|
(3)
|
The address for Mr. Bloom is 31 N. Suffolk Lane, Lake Forest, Illinois 60045. Mr. Bloom does not own any shares of stock. However, he holds options to purchase 100,000 shares of our common stock.
|
|
(4)
|
The address for the Roberti Jacobs Family Trust is 31 N. Suffolk Lane, Lake Forest, Illinois 60045. The Roberti Jacobs Family Trust irrevocably conveyed all of its voting power to Gerard M. Jacobs pursuant to the 2007 shareholder agreement described above. Mr. Jacobs is one of the grantors of the trust
corpus, Mr. Jacobs’ mother in law Joan B. Roberti is the trustee, and Mr. Jacobs’ children are the beneficiaries. The trust is irrevocable. The Trust’s 4,666,497 shares consist of (a) 1,166,497 shares owned, and (b) 3,500,000 warrants owned at $0.10 per share. The Trust has the right, for 90 days after the closing of the Cogility merger, to invest an additional $350,000 into the Company in accordance with the private placement in which it participated, and if it does so, it will acquire an additional 3,500,000 warrants at $0.10 per share.
|
|
(5)
|
The address for Mr. Greene is 6 Joliet Drive, Coto de Caza, California 92679. Mr. Greene does not own any shares of stock. However, he holds options and warrants to purchase a total of 350,000 shares of our common stock, consisting of (a) 100,000 options at $0.10 per share, the vesting of which is contingent upon the closing of the merger with Cogility, and (b) 250,000 warrants at $0.10 per share. Mr. Greene has the right, for 90 days after the closing of the Cogility merger, to invest an additional $25,000 into the Company in accordance with the private placement in which he participated, and if he does so, he will acquire an additional 250,000 warrants at $0.10 per share.
|
|
(6)
|
The address for Mr. McCaffrey is 31 N. Suffolk Lane, Lake Forest, Illinois 60045. Mr. McCaffrey does not own any shares of stock. However, he holds options to purchase 100,000 shares of our common stock.
|
|
(7)
|
The address for Mr. Morrissy is 31 N. Suffolk Lane, Lake Forest, Illinois 60045. Mr. Morrissy does not own any shares of stock. However, he holds options to purchase 100,000 shares of our common stock.
|
|
(8)
|
The address for Mr. Mesolella is 27 Paddock Drive, Lincoln, Road Island 02865. Mr. Mesolella does not own any shares of stock. However, he holds options and warrants to purchase a total of 350,000 shares of our common stock, consisting of (a) 100,000 options at $0.10 per share, the vesting of which is contingent upon the closing of the merger with Cogility, and (b) 250,000 warrants at $0.10 per share. Mr. Mesolella has the right, for 90 days after the closing of the Cogility merger, to invest an additional $25,000 into the Company in accordance with the private placement in which he participated, and if he does so, he will acquire an additional 250,000 warrants at $0.10 per share.
|
|
(9)
|
The address for Mr. Keller is 25991 W. Herman Ave., Antioch, IL 60002. Mr. Keller does not own any shares of stock. However, he holds warrants to purchase a total of 3,000,000 common stock shares, consisting of (a) 2,500,000 warrants at $0.10 per share, and (b) one of his affiliates, Glendenning Capital, Inc., has 500,000 warrants at $0.10 per share. Mr. Keller has the right, for 90 days after the closing of the Cogility merger, to invest an additional $250,000 into the Company in accordance with the private placement in which he participated, and if he does so, he will acquire an additional 2,500,000 warrants at $0.10 per share. Also, Glendenning Capital, Inc. has the right, for 90 days after the closing of the Cogility merger, to invest an additional $50,000 into the Company in accordance with the private placement in which it participated and if it does so, it will acquire an additional 500,000 warrants at $0.10 per share.
|
|
(10)
|
The address for the Heiders is 1100 Queen Anne Road, Woodstock, Illinois 60098. The Heiders do not own any shares of stock. However, they hold warrants to purchase a total of 1,500,000 common stock shares at $0.10 per share. The Heiders have the right, for 90 days after the closing of the Cogility merger, to invest an additional $150,000 into the Company in accordance with the private placement in which they participated, and if they do so, they will acquire an additional 1,500,000 warrants at $0.10 per share.
|
|
(11)
|
Gerard M. Jacobs has rights to vote the shares of the Roberti Jacobs Family Trust and L. Dee Hall. These shares have not been applied as beneficially owned by both Mr. Jacobs and the respective stockholders, but not counted more than once in the total column.
|
|
Equity Compensation Plan Information
|
|||
|
Plan Category
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights
|
Weighted-average exercise price of outstanding options, warrants and rights
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
|
|
Equity compensation plans approved by security holders
|
12,600,000(1)
|
$0.06
|
1,117,925(2)
|
|
Equity compensation plans not approved by security holders
|
-
|
-
|
-
|
|
Total
|
12,600,000(3)(4)
|
$0.06
|
1,117,925(5)
|
|
-
|
-
|
||
|
1.
|
In November 2010, Acquired Sales granted these stock options to the members of management that participated in structuring the financing and the merger with Cogility. Those stock options were for the purchase of 12,600,000 pre-split common shares at $0.10 per share, or 630,000 post-split common shares at $2.00 per share. The options vest upon the occurrence of the merger, which as of the date of this filing, has not occurred. The grant-date fair value of these stock options of $801,762 less $308,787 already included in Acquired Sales’ operations is recognized as compensation expense.
|
|
2.
|
Prior to the merger, Cogility had stock options outstanding that permit the holders thereof to purchase 5,925,000 Cogility common shares at prices ranging from $0.001 to $1.40 per share. In the merger transaction, the Cogility option holders are to exchange these stock options for 1,117,925 Acquired Sales stock options exercisable at prices ranging from $0.001 to $5.00 per share. The exchange of these stock options is considered to be part of the recapitalization of Cogility and is not a modification of the Cogility stock options. There are 3,295,000 of these Cogility stock options that are exchangeable for 621,698 Acquired Sales stock options that vested during 2011 upon Acquired Sales obtaining at least $500,000 of financing and the remaining Cogility stock options vest upon occurrence of the merger with the Acquired Sales subsidiary.
|
|
3.
|
Gerard M. Jacobs is the only executive officer of the Company. He has received 12,100,000 options.
|
|
4.
|
The current directors who are not executive officers have collectively received 500,000 options.
|
|
5.
|
Of the 1,117,925 Cogility options, Gerard M. Jacobs holds options that are to be exchanged for 571,698 Acquired Sales options should the acquisition of Cogility be completed. This would increase the number of post-reverse split Acquired Sales options held by Mr. Jacobs to 1,176,698 from 605,000 presently held. Roger S. Greene and Vincent J. Mesolella each hold Cogility options that are to be exchanged for 25,000 Acquired Sales options should the acquisition of Cogility be completed. This would increase the number of post-reverse split Acquired Sales options held by each of Mr. Greene and Mr. Mesolella to 30,000 from 5,000 presently held.
|
|
Form 10-SB
3.1
3.2
3.3
3.4
3.5
3.6
|
March 23, 2007
Articles of Incorporation dated December 12, 1985
Amended Articles of Incorporation Dated July 1992
Amended Articles of Incorporation Dated November 1996
Amended Articles of Incorporation Dated June 1999
Amended Articles of Incorporation Dated January 25, 2006
Amended Bylaws
|
|
Form 8-K
5.01
|
August 2, 2007
Shareholder Agreement
|
|
Form 10Q
10.1
10.2
10.3
10.4
10.5
10.6
|
May 18, 2009
Private Merchant Banking Agreement-Anniston Capital, Inc.
Warrant Agreement #1-Anniston Capital, Inc.
Warrant Agreement #2-Anniston Capital, Inc.
$100,000 Promissory Note – December 1, 2007
$10,000 Promissory Note – January 30, 2008
$10,000 Promissory Note – November 9, 2008
|
|
Form 10-K
10.7
|
August 20, 2010
$4,000 Promissory Note – April 19, 2010
|
|
Form 8-K
10.1
99.1
|
November 5, 2010
Letter of Intent Agreement Cogility Software dated November 4, 2010
Press Release
|
|
Form 10-K
10.8
|
December 17, 2010
$20,000 Promissory Note – October 12, 2010
|
|
This Form 10-K
4.1
4.2
10.10
31.1
32.1
|
Form of Note 3%
Form of Warrant
Subscription Agreement
Certification of principal executive officer and principal financial officer
pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as
amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002 executed by Gerard M. Jacobs
Certification of principal executive officer and principal financial officer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002 executed by Gerard M. Jacobs
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|